Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy

SCHMIDT, ANDRÉ; RAO-MELACINI, PURNIMA; DIAS ROMANO, MINNA MOREIRA; AVEZUM, ÁLVARO; RASSI, ANIS; BONILLA, RINA; VILLENA, ERICK; MACIEL, BENEDITO CARLOS; YUSUF, SALIM; MARIN-NETO, JOSÉ ANTÔNIO; MATTOS, ANTÔNIO; SOSA-ESTANI, SERGIO; MORILLO, CARLOS A.

JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY : OFFICIAL PUBLICATION OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY.

MOSBY-ELSEVIER

Año: 2019 vol. 32 p. 286 - 295

0894-7317

Background: Serial echocardiographic studies in chronic Chagas cardiomyopathy are scarce. The aims of this study were to evaluate whether therapy with benznidazole modifies the progression of cardiac impairment and to identify baseline echocardiographic parameters related to prognosis. Methods: A prospective substudy was conducted in 1,508 patients with chronic Chagas cardiomyopathy randomized to benznidazole or placebo, who underwent two-dimensional echocardiography at enrollment, 2 years, and final follow-up (5.4 years). Left ventricular (LV) ejection fraction, LV wall motion score index (WMSI), indexed left atrial volume, and chamber dimensions were collected and correlated to all-cause death and a composite hard outcome using univariate and multivariate analyses. Results: At enrollment, most patients had normal chamber dimensions, and 70.5% had preserved LV ejection fractions. During follow-up, all chamber dimensions increased similarly in both treatment arms. LV ejection fraction was comparably reduced (55.7 ± 12.7% to 52.1 ± 14.6% vs 56.3 ± 12.7% to 52.8 ± 14.1%) and LV WMSI similarly increased (1.31 ± 0.41 to 1.49 ± 0.03 and 1.27 ± 0.38 to 1.51 ± 0.03) for the benznidazole and placebo groups, respectively (P >.05). A higher baseline LV WMSI was identified in subjects who died compared with those alive at final echocardiography (1.76 ± 0.517 vs 1.271 ± 0.393, P